Janney Montgomery Scott LLC Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janney Montgomery Scott LLC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,806 shares of the medical equipment provider’s stock after purchasing an additional 5,753 shares during the period. Janney Montgomery Scott LLC’s holdings in Lantheus were worth $1,772,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC grew its stake in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the 3rd quarter valued at $25,000. Finally, CWM LLC lifted its position in shares of Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 290 shares during the period. Institutional investors own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $92.51 on Monday. The company has a fifty day moving average of $92.05 and a 200 day moving average of $99.52. The company has a market capitalization of $6.43 billion, a P/E ratio of 15.39 and a beta of 0.46. Lantheus Holdings, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $126.89.

Analysts Set New Price Targets

Several brokerages recently issued reports on LNTH. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.